- Home
- HAFN vs CPRX Comparison
HAFN vs CPRX Comparison
Compare HAFN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- CPRX
- Stock Information
- Founded
- HAFN 2012
- CPRX 2002
- Country
- HAFN Bermuda
- CPRX United States
- Employees
- HAFN N/A
- CPRX N/A
- Industry
- HAFN
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- CPRX Health Care
- Exchange
- HAFN Nasdaq
- CPRX Nasdaq
- Market Cap
- HAFN 3.0B
- CPRX 2.8B
- IPO Year
- HAFN N/A
- CPRX 2006
- Fundamental
- Price
- HAFN $5.26
- CPRX $20.60
- Analyst Decision
- HAFN Strong Buy
- CPRX Strong Buy
- Analyst Count
- HAFN 1
- CPRX 6
- Target Price
- HAFN $10.00
- CPRX $30.50
- AVG Volume (30 Days)
- HAFN 2.1M
- CPRX 984.3K
- Earning Date
- HAFN 01-01-0001
- CPRX 11-06-2024
- Dividend Yield
- HAFN 30.73%
- CPRX N/A
- EPS Growth
- HAFN N/A
- CPRX 114.68
- EPS
- HAFN 1.56
- CPRX 1.18
- Revenue
- HAFN $2,970,261,000.00
- CPRX $460,482,000.00
- Revenue This Year
- HAFN N/A
- CPRX $21.99
- Revenue Next Year
- HAFN N/A
- CPRX $17.95
- P/E Ratio
- HAFN $3.37
- CPRX $17.48
- Revenue Growth
- HAFN 18.39
- CPRX 32.17
- 52 Week Low
- HAFN $5.13
- CPRX $13.00
- 52 Week High
- HAFN $8.99
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- CPRX 39.71
- Support Level
- HAFN N/A
- CPRX $21.30
- Resistance Level
- HAFN N/A
- CPRX $24.27
- Average True Range (ATR)
- HAFN 0.00
- CPRX 0.79
- MACD
- HAFN 0.00
- CPRX -0.18
- Stochastic Oscillator
- HAFN 0.00
- CPRX 4.18
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.